Pricing Log in Create free account

Genmab A/S Sponsored ADR (GMAB) vs Roivant Sciences Ltd. (ROIV)

Genmab A/S Sponsored ADR and Roivant Sciences Ltd. are both Biotechnology companies. Genmab A/S Sponsored ADR is the larger, with a market value of $31.5B against $26.5B — 1.2× the size. Roivant Sciences Ltd. has negative trailing earnings, so its P/E is not meaningful; Genmab A/S Sponsored ADR trades at 41.7×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against −67.6%. Genmab A/S Sponsored ADR has the higher net margin (19.1% vs −3,535.0%) and the higher return on invested capital (6.99% vs −34.5%). Across the 19 metrics below, Genmab A/S Sponsored ADR leads on 15 and Roivant Sciences Ltd. on 4.

Valuation

Metric GMAB ROIV Biotechnology median
P/E 41.72 n/m 10.26
P/S 7.87 3,528.29 9.18
P/B 5.46 5.40 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 30.99 n/m 0.65
EV/Sales 8.75 3,061.16 8.98
Earnings yield 2.40% (1.03%) (34.89%)
Free cash flow yield (19.53%) (3.09%) (24.52%)

Profitability

Metric GMAB ROIV Biotechnology median
Gross margin 93.03% 81.21% 65.16%
Operating margin 25.95% (7,914.75%) 0.00%
Net margin 19.08% (3,534.96%) 0.00%
Free cash flow margin (153.64%) (10,901.00%) 0.00%
Return on equity 14.00% (5.47%) (50.12%)
Return on assets 8.30% (5.15%) (45.60%)
Return on invested capital 6.99% (34.51%) 0.00%

Growth

Metric GMAB ROIV Biotechnology median
Revenue growth (TTM) 22.26% (67.58%) 6.26%
EPS growth (last fiscal year) (12.50%) (125.00%) 29.88%
Revenue growth, 5-year CAGR 19.15% (19.07%) 9.75%
Net income growth, 5-year CAGR 5.73% 0.00% 0.00%

Health

Metric GMAB ROIV Biotechnology median
Debt to equity 0.86 0.00 0.00
Current ratio 2.46 16.72 4.89
Net debt to EBITDA 3.13 8.39 1.01

Dividend

Metric GMAB ROIV Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GMAB ROIV Biotechnology median
Market cap 31.51b 26.45b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack